Please assess the completion status of the following clinical trial:

Trial Title: Memory for Action in Neurological Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria for 3 arms:~* Patient affiliated to a social security system~* Age between 55 and 80 years~* Normal vision and hearing or successfully corrected~* French mother tongue~* Signature of consent by participants~Specific criteria for inclusion of MA patients:~* Probable AD diagnosis made by a neurologist (McKhann et al., 2011)~* Mini-Mental State Examination (MMSE): score \> 22~* Stable treatment for two months minimum.~Specific criteria for inclusion of PD patients:~* PD diagnosed by a neurologist (Postuma et al., 2015)~* Stable treatment for two months minimum.~* Mini-Mental State Examination (MMSE): score \> 27~* Under dopaminergic treatment~Exclusion Criteria for 3 arms:~* Other neurological or psychiatric history~* Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD; Zigmond \& Snaith, 1983)~* Inability to communicate~* Significant impairment of judgment~* Delusional or psychotic state~Criteria common for non-inclusion of AD and PD patients:~* Other neurological or psychiatric history~* Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD; Zigmond \& Snaith, 1983)~* Inability to communicate~* Significant impairment of judgment~* Delusional or psychotic state~Criteria for non-inclusion of PD patients:~- Motor fluctuations~Criteria for non-inclusion of controls:~* Psychiatric or neurological disorders~* Anxiety and depressive symptoms (assessed by the scale of depression-anxiety HAD; Zigmond \& Snaith, 1983)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- patients with Alzheimer disease (Type: ACTIVE_COMPARATOR): Behavioral: Cognitive tests Only patients with Alzheimer disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
- patients with Parkinson disease (Type: ACTIVE_COMPARATOR): Behavioral: Cognitive tests Only patients with Parkinson disease will be included in this arm. Patients will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
- healthy controls (Type: SHAM_COMPARATOR): Behavioral: Cognitive tests Only patients with healthy controls will be included in this arm. Controls will perform different tasks : MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond \& Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues